China Pharma Holdings (CPHI) Receivables (2010 - 2026)

China Pharma Holdings has reported Receivables for 17 years, with the latest figure at $267353.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 27.34% year-over-year to $267353.0; the trailing twelve-month figure through Mar 2026 stood at $267353.0 (down 27.34% YoY), and the FY2025 full-year result was $290673.0, down 97.9% from the prior year.
• Receivables for Q1 2026 stood at $267353.0, down from $290673.0 in the prior quarter.
• The five-year high for Receivables was $14.2 million in Q1 2024, with the low at $267353.0 in Q1 2026.
• Historically, Receivables has averaged $2.2 million across 5 years, with a median of $397156.0 in 2023.
• Annual changes were most pronounced in 2024 — Receivables soared 2477.0% — and 2025, when it sank 97.9%.
• China Pharma Holdings' Receivables stood at $450670.0 in 2022, then surged by 46.98% to $662392.0 in 2023, then surged by 1990.85% to $13.8 million in 2024, then slumped by 97.9% to $290673.0 in 2025, then retreated by 8.02% to $267353.0 in 2026.
• The last three Receivables figures came in at $267353.0 (Q1 2026), $290673.0 (Q4 2025), and $285913.0 (Q3 2025), per Business Quant data.